'Bevacizumab' presentation slideshows

1.09k views • 66 slides

1.08k views • 52 slides

Phase 2 Evaluation of Intravitreal Bevacizumab for DME

Phase 2 Evaluation of Intravitreal Bevacizumab for DME. Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health and Human Services. Study Objectives.

586 views • 44 slides

Forging a new standard in metastatic CRC

Forging a new standard in metastatic CRC. Eric Van Cutsem University Hospital Gasthuisberg Leuven, Belgium. Advances in the treatment of mCRC. 1980 1985 1990 1995 2000 2005 2010. Best supportive care. 5-FU.

560 views • 44 slides

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update. ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update. Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab use beyond first progression linked to improvement in survival outcomes

651 views • 40 slides

Treatment of Metastatic colorectal cancer

Treatment of Metastatic colorectal cancer. Robert Jones Consultant Senior Lecturer Medical Oncology. 71 yo man presents with lethargy, right sided abdominal discomfort and a raised CEA CT CAP shows Liver and Lung metastases and a mass in the region of the sigmoid colon

861 views • 40 slides

Anti-angiogenic therapy: a new approach to the treatment of metastatic breast cancer

Anti-angiogenic therapy: a new approach to the treatment of metastatic breast cancer. Kathy Miller Indiana University School of Medicine, USA. VEGF is a central mediator of angiogenesis, the formation of new blood vessels. Hemangioblast. SMC progenitor. Endothelial progenitors. SMC.

676 views • 37 slides

LB Saltz, HJ Lenz, H Kindler, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, M Gonen,

Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan versus Cetuximab/Bevacizumab in Irinotecan-Refractory Colorectal Cancer. LB Saltz, HJ Lenz, H Kindler, H Hochster, S Wadler, P Hoff, N Kemeny, E Hollywood, M Gonen, S Wetherbee, H Chen. Objectives.

322 views • 25 slides

HS Hochster

364 views • 23 slides

Disclosure

287 views • 22 slides

Chemobiologic Treatment of Advanced Adenocarcinoma: Role of VEGF Inhibition

344 views • 20 slides

NYU Medical Grand Rounds Clinical Vignette

NYU Medical Grand Rounds Clinical Vignette. Pavan Bhatraju MD, PGY-II June 19, 2012. U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS. Chief Complaint. 72 year old male who presented with dyspnea on exertion and fatigue for the last 3 weeks. U NITED S TATES

284 views • 13 slides

EFFECT OF RESVERATROL AND BEVACIZUMAB ON EXPERIMENTAL CORNEAL NEOVASCULARIZATION

314 views • 12 slides

AVADO PFS Analysis (ITT Population)

300 views • 11 slides

The use of subconjuntival bevacizumab for treatment of the corneal neovascularisation

304 views • 11 slides

1 Bear HD et al. Proc ASCO 2011;Abstract LBA1005.

212 views • 10 slides

Thank you for downloading this update. Please feel free to use it for educational purposes.

ASCO 2010 Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study.

226 views • 7 slides

Crown J et al. Proc SABCS 2010;Abstract P5-10-17.

Bevacizumab (Bev) in Combination with Docetaxel (T) and Cyclophosphamide (C) as Adjuvant Treatment (AdjRx) for Patients (Pts) with Early Stage (ES) Breast Cancer (BrCa) and Normal HER-2 Status. A Pilot Evaluation. Crown J et al. Proc SABCS 2010;Abstract P5-10-17. Methods.

227 views • 7 slides

GCIG trials for rare ovarian histologies

GCIG trials for rare ovarian histologies. Edward L. Trimble, MD, MPH National Cancer Institute, USA. Open trials. Japanese Gynecologic Oncology Group 3017 Carboplatin/ paclitaxel versus carboplatin/ irinotecan Accrual to date: 345/planned accrual: 650

225 views • 7 slides

Kristensen G et al. Proc ASCO 2011;Abstract LBA5006.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer. Kristensen G et al. Proc ASCO 2011;Abstract LBA5006. Background.

182 views • 6 slides